MP
BMY.RT

Mangrove Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Mangrove Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,397,884
Closed -$9.94M – 397
2020
Q4 		$9.94M Buy
14,397,884
+4,312,071
+43% +$9.18M 1.36% 11
2020
Q3 		$22.7M Buy
10,085,813
+6,139,668
+156% +$17.5M 2.87% 10
2020
Q2 		$14.1M Buy
3,946,145
+2,115,545
+116% +$7.63M 3.45% 10
2020
Q1 		$6.96M Buy
+1,830,600
New +$6.03M 0.96% 25

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Mangrove Partners's BMY.RT Position: Q1 2021 in Review

Mangrove Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 14,397,884 shares — an estimated $9.94M sold.

Mangrove Partners first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $22.7M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Mangrove Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Mangrove Partners sold 14,397,884 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $9.94M.
  • Mangrove Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Mangrove Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $22.7M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Mangrove Partners's 13F filing for Q1 2021, filed 17 May 2021.